Synthon's ADCs could hit the clinic next year

Lead candidate combines Herceptin with a duocarmycin analog payload

Synthon Biopharmaceuticals' lead second-generation antibody-drug conjugate (ADC) has shown promise in breast and lung cancers grafted into animals, and a clinical trial is planned for 2014.

The company's ADCs use anti-cancer antibodies linked to cancer drugs known as duocarmycin analogs, which disrupt cancer cell DNA at any stage of the cell cycle and have potential against multidrug-resistant cancers. By targeting tumors specifically, ADCs, also known as armed antibodies, have the potential to reduce side effects and improve efficacy.

By including the anti-HER2 antibody trastuzumab, Genentech/Roche's ($RHHBY) Herceptin, Synthon Biopharmaceuticals' lead ADC has potential in cancers overexpressing HER2, such as metastatic breast cancer and non-small cell lung cancer.

Animals with xenografts from patients with breast cancer or non-small cell lung cancer treated with this lead candidate had complete tumor remission while those treated with the antibody alone showed no effect. The Synthon ADCs reportedly have a better toxicity profile and therapeutic index than other ADCs in development.

Synthon Biopharmaceuticals has opened a new GMP facility in the Netherlands where it will produce ADCs for clinical trials and perform early launches of the drugs.

- read the press release

Related Articles:
Seattle Genetics' next-gen antibody-drug conjugate tackles leukemia in the lab
Upstart Valor launches with plans to develop armed antibody cancer drugs
Fujifilm pairs with Piramal on antibody drug conjugates
Biotecnol and PolyTherics team up to develop drug conjugates